Nucleotide metabolism, leukodystrophies, and CNS pathology
Journal of Inherited Metabolic Disease · 2024-09 · 47 (5) · 860-875
DOI: 10.1002/jimd.12721 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Inherited Metabolic Disease, online erschienen am 29.02.2024. Verfasst von Francesco Gavazzi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA. Hauptthemen laut MEDLINE: Nervous System Malformations. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 176 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NINDS NIH HHS.
Abstract (Originalsprache)
The balance between a protective and a destructive immune response can be precarious, as exemplified by inborn errors in nucleotide metabolism. This class of inherited disorders, which mimics infection, can result in systemic injury and severe neurologic outcomes. The most common of these disorders is Aicardi Goutières syndrome (AGS). AGS results in a phenotype similar to “TORCH” infections ( Toxoplasma gondii , Other [Zika virus (ZIKV), human immunodeficiency virus (HIV)], Rubella virus, human Cytomegalovirus [HCMV], and Herpesviruses), but with sustained inflammation and ongoing potential for complications. AGS was first described in the early 1980s as familial clusters of “TORCH” infections, with severe neurology impairment, microcephaly, and basal ganglia calcifications (Aicardi & Goutières, Ann Neurol , 1984;15:49–54) and was associated with chronic cerebrospinal fluid (CSF) lymphocytosis and elevated type I interferon levels (Goutières et al., Ann Neurol , 1998;44:900–907). Since its first description, the clinical spectrum of AGS has dramatically expanded from the initial cohorts of children with severe impairment to including individuals with average intelligence and mild spastic paraparesis. This broad spectrum of potential clinical manifestations can result in a delayed diagnosis, which families cite as a major stressor. Additionally, a timely diagnosis is increasingly critical with emerging therapies targeting the interferon signaling pathway. Despite the many gains in understanding about AGS, there are still many gaps in our understanding of the cell‐type drivers of pathology and characterization of modifying variables that influence clinical outcomes and achievement of timely diagnosis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of Neurology, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA.
- Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Förderung
- NINDS NIH HHS
Zitieren
APA
Gavazzi, F., Gonzalez, C. D., Arnold, K., Swantkowski, M., Charlton, L., Modesti, N., Dar, A. A., Vanderver, A., Bennett, M., & Adang, L. A. (2024). Nucleotide metabolism, leukodystrophies, and CNS pathology. Journal of Inherited Metabolic Disease, 47(5), 860-875. https://doi.org/10.1002/jimd.12721
Vancouver
Gavazzi F, Gonzalez CD, Arnold K, Swantkowski M, Charlton L, Modesti N, et al. Nucleotide metabolism, leukodystrophies, and CNS pathology. Journal of Inherited Metabolic Disease. 2024;47(5):860-875. doi:10.1002/jimd.12721
BibTeX
@article{Gavazzi2024,
author = {Gavazzi, Francesco and Gonzalez, Carlos Dominguez and Arnold, Kaley and Swantkowski, Meghan and Charlton, Lauren and Modesti, Nicholson and Dar, Asif A and Vanderver, Adeline and Bennett, Mariko and Adang, Laura A},
title = {Nucleotide metabolism, leukodystrophies, and CNS pathology},
journal = {Journal of Inherited Metabolic Disease},
year = {2024},
volume = {47},
number = {5},
pages = {860--875},
doi = {10.1002/jimd.12721}
}
EUVIMED